Aditya Bagrodia, MD, FACS, presented “Point-Counterpoint: Erectile Dysfunction After Local Therapies: PDE5 Inhibitors and Early Penile Rehab Improves ED Recovery Following Radical Surgery​ – Con” during the 30th Annual Perspectives in Urology: Point-Counterpoint, on March 10, 2023, at Humphreys Half Moon Inn, San Diego, California.

How to cite: Bagrodia, Aditya. “Point-Counterpoint: Erectile Dysfunction After Local Therapies: PDE5 Inhibitors and Early Penile Rehab Improves ED Recovery Following Radical Surgery – Con.” March 10, 2023. Accessed Sep 2025. https://grandroundsinurology.com/point-counterpoint-erectile-dysfunction-after-local-therapies-pde5-inhibitors-and-early-penile-rehab-improves-ed-recovery-following-radical-surgery-con/

Point-Counterpoint: Erectile Dysfunction After Local Therapies: PDE5 Inhibitors and Early Penile Rehab Improves ED Recovery Following Radical Surgery – Con – Summary

Aditya Bagrodia, MD, FACS, Associate Professor of Urology and Genitourinary Oncology Team Lead at the University of California, San Diego, presents the cons of using PDE5 inhibitors and early penile rehabilitation to treat erectile dysfunction post-radical prostatectomy. In this presentation, Dr. Bagrodia discusses:

    • The known adverse effects of early use of PDE5is in patients
    • The failure of PDE5is to out-perform placebos
    • The strengths and weaknesses of known treatment options for post-operative erectile dysfunction

This lecture is part of a Point-Counterpoint debate. Its opposing lecture is “Point-Counterpoint: Erectile Dysfunction After Local Therapies: PDE5 Inhibitors and Early Penile Rehab Improves ED Recovery Following Radical Surgery – Pro.”

About the 30th Annual Perspectives in Urology: Point Counterpoint conference: Presented by Program Chair and Grand Rounds in Urology Editor-in-Chief E. David Crawford, MD, this conference brought together leading experts in urology, medical oncology, and radiation oncology to discuss and debate the latest topics in genitourinary cancers, primarily prostate cancer and bladder cancer. This interactive conference offered topical lectures, pro/con debates, interesting-case presentations, interactive panel discussions, and interactive audience and faculty networking. 

ABOUT THE AUTHOR

+ posts

Aditya Bagrodia, MD, FACS, is a Professor of Urology and the Disease Team Co-Leader for Genitourinary Cancer at the University of California, San Diego. Dr. Bagrodia’s clinical and research interests on understanding molecular attributes of germ cell tumors, which cause testicular cancer, with the goal of ultimately improving treatments and clinical care. He also has been actively involved in understanding and overcoming societal and epidemiological barriers to optimal care in testicular cancer patients. He also has expertise in minimally invasive approaches to urologic surgery.